MDMA is a synthetic stimulant and psychoactive drug chemically related to amphetamine. Its full name is 3,4-methylenedioxymethamphetamine, and it’s widely known by street names like ecstasy (pressed pills) and molly (crystal or powder form). It produces feelings of emotional closeness, heightened sensory perception, and elevated mood, primarily by flooding the brain with serotonin.
How MDMA Works in the Brain
MDMA’s primary target is the serotonin transporter, the protein responsible for recycling serotonin back into nerve cells after it’s been released. MDMA disrupts this process in two ways: it blocks the transporter from pulling serotonin back in, and it actually reverses the transporter’s direction, pumping stored serotonin out into the space between neurons. The result is a massive surge of serotonin activity, which drives most of the drug’s signature effects on mood, emotional openness, and sensory perception.
MDMA also increases dopamine levels through a similar mechanism, though to a lesser degree. Dopamine contributes to the sense of energy and euphoria. A third chemical messenger, norepinephrine, is also affected, which explains the physical stimulant effects like increased heart rate and blood pressure.
What MDMA Feels Like
MDMA is classified as an “entactogen,” a term meaning it produces feelings of closeness and emotional connection with others. Users commonly describe a strong sense of empathy, trust, and warmth toward the people around them. Colors appear brighter and sounds feel more intense.
Effects typically begin 30 to 60 minutes after swallowing a dose, peak around one to two hours in, and largely subside within about six hours. During peak effects, people report elevated positive mood and increased feelings of arousal and energy. Recreational doses generally fall between 50 mg and 150 mg, with most users taking one or two tablets over the course of an evening. Doses significantly above that range, especially combined with other substances, carry substantially higher risk of toxic outcomes.
Physical Risks and Side Effects
The two most dangerous acute complications of MDMA are overheating and dangerously low sodium levels, and the two are closely linked.
MDMA raises body temperature on its own, and when combined with hours of dancing in a hot, crowded venue, core temperature can climb to dangerous levels (up to 43°C/109°F in severe cases). Heavy sweating depletes both water and electrolytes, especially sodium. In response, many users drink large amounts of water, sometimes far more than their body can handle. This creates a second problem: MDMA triggers the release of antidiuretic hormone from the pituitary gland, which tells the kidneys to hold onto water rather than pass it as urine. The combination of excessive water intake and reduced urine output can dilute blood sodium to critically low levels, a condition called hyponatremia. Severe cases cause brain swelling and can be fatal.
Other common side effects include jaw clenching, nausea, muscle cramping, blurred vision, and a rapid heartbeat. In the days following use, many people experience a noticeable dip in mood, sometimes called a “comedown,” as serotonin stores take time to replenish.
Long-Term Effects on the Brain
Brain imaging studies have shown altered serotonin function in regular ecstasy users, and some of these changes appear to persist even after long periods without the drug. The scientific debate centers on whether these changes represent actual structural damage to serotonin-producing neurons or a long-term downregulation, meaning the system dials itself back without physically breaking. One clinical study found that people who had been drug-free for 20 weeks or longer showed no measurable reduction in serotonin transporter levels, suggesting some degree of recovery is possible. The picture remains incomplete, and heavier, more frequent use appears to carry greater risk of lasting effects on mood, memory, and cognitive function.
Dangerous Drug Interactions
Combining MDMA with certain medications can be life-threatening. The most dangerous combination is MDMA with MAOIs, an older class of antidepressants (and also found in some dietary supplements like Syrian rue). MAOIs prevent the breakdown of serotonin, and when paired with MDMA’s serotonin-releasing effects, the result can be severe serotonin syndrome: dangerously high body temperature, seizures, altered consciousness, and death. This combination has been responsible for the majority of deaths in published case studies involving MDMA and psychiatric medications.
Common antidepressants also pose risks in uncontrolled settings. A large surveillance study of FDA adverse event reports found that several antidepressants increased the odds of death when combined with MDMA. Bupropion carried the highest risk among antidepressants, likely because both drugs are stimulants that can lower the seizure threshold and increase each other’s blood concentrations. Sertraline, venlafaxine, and citalopram (all SSRIs or related drugs) also showed elevated risk. Combining MDMA with other stimulants like amphetamines tripled the adjusted odds of death, and even alcohol roughly doubled the risk.
Purity and Adulterants
What’s sold as ecstasy or molly frequently contains other substances. In a survey of ecstasy users in New York City’s electronic dance music scene, about half reported that their ecstasy had contained something other than MDMA. Nearly half found out or suspected their pills contained methamphetamine or amphetamine. About a quarter had encountered cocaine as an adulterant. Fentanyl and its analogs, while less commonly identified in that particular study, represent an especially dangerous risk because even trace amounts of a highly potent opioid can cause fatal overdose in someone who has no opioid tolerance.
This inconsistency in street supply means that many of the harms attributed to “ecstasy” may actually be caused by unknown adulterants, making the unregulated drug supply one of the most significant risk factors associated with MDMA use.
MDMA as a Potential Therapy
MDMA’s ability to reduce fear and increase feelings of trust led researchers to explore it as a tool for psychotherapy, particularly for post-traumatic stress disorder. The American chemist Alexander Shulgin re-synthesized MDMA in 1976, tried it himself, and the following year introduced it to a psychotherapist named Leo Zeff, who began using it as an aid in therapy sessions. It spread among therapists through the late 1970s and early 1980s before the U.S. government placed it on Schedule I in 1985, making it illegal for any use.
Decades later, clinical trials revisited the idea. Two phase 3 trials showed that MDMA combined with psychotherapy produced greater reductions in PTSD symptoms compared to psychotherapy with a placebo. However, in 2024, the FDA declined to approve the treatment, requesting an additional clinical trial. An advisory committee had voted 10 to 1 that the existing data did not show benefits outweighing risks, partly because MDMA’s obvious mind-altering effects made it nearly impossible for participants to not know whether they received the real drug or a placebo, undermining the reliability of the results. MDMA remains a Schedule I substance in the United States with no approved medical use.